Kelsey Stephen Michael's Form 4 filing
Revolution Medicines, Inc. (RVMD) · filed Sep 15, 2025
- Accession no.
- 0001610717-25-000339
- Filed
- Sep 15, 2025
- Trade date
- Sep 11-15, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 6 non-derivative transactions and 2 derivative transactions. Open-market sales total $5.56M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kelsey Stephen MichaelCIK 0001462808 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 11, 2025 | Common Stock | MOption exerciseAcquired | +100,000 | $4.73 | +$473,000 | 389,414 | Direct | |
| Sep 11, 2025 | Common Stock | SSaleDisposed | −44,059 | $43.58F3 | −$1,920,091.22 | 345,355 | Direct | |
| Sep 11, 2025 | Common Stock | SSaleDisposed | −55,941 | $44.48F4 | −$2,488,255.68 | 289,414 | Direct | |
| Sep 15, 2025 | Common Stock | MOption exerciseAcquired | +25,000 | $4.73 | +$118,250 | 314,414 | Direct | |
| Sep 15, 2025 | Common Stock | SSaleDisposed | −23,682 | $45.92F5 | −$1,087,477.44 | 290,732 | Direct | |
| Sep 15, 2025 | Common Stock | SSaleDisposed | −1,318 | $46.93F6 | −$61,853.74 | 289,414 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 11, 2025 | Common Stock | MOption exerciseDisposed | −100,000 | $0.00 | $0 | 55,055 | Direct | |
| Sep 15, 2025 | Common Stock | MOption exerciseDisposed | −25,000 | $0.00 | $0 | 30,055 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The transaction was executed in multiple trades in prices ranging from $43.12 to $44.09, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F4
The transaction was executed in multiple trades in prices ranging from $44.12 to $44.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F5
The transaction was executed in multiple trades in prices ranging from $45.4650 to $46.46, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F6
The transaction was executed in multiple trades in prices ranging from $46.5450 to $47.21, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Remarks
President, Research and Development